Once-weekly Byetta could get similar thyroid cancer warning as Victoza
This article was originally published in Scrip
Executive Summary
Amylin/Lilly's Bydureon, a once-weekly formulation of the twice-daily dosed Byetta (exenatide), could get a similar "black box" warning for risk of rare medullary thyroid cancer as Novo Nordisk's recently approved rival type 2 diabetes drug Victoza (liraglutide), judging from the comments of a US FDA official in a document posted recently on the agency's website that discusses the basis of Victoza's approval.